Dexmethylphenidate Hydrochloride is a small molecule commercialized by Cingulate, with a leading Phase III program in Attention Deficit Hyperactivity Disorder (ADHD). According to Globaldata, it is involved in 8 clinical trials, of which 5 were completed, 2 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of Dexmethylphenidate Hydrochloride’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for Dexmethylphenidate Hydrochloride is expected to reach an annual total of $201 mn by 2034 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Dexmethylphenidate Hydrochloride Overview

Dexmethylphenidate hydrochloride is under development for the treatment of attention deficit hyperactivity disorder (ADHD). The drug candidate is administered orally and formulated as tablet. It is developed based on Cingulate’s innovative Precision Timed Release (PTR) drug delivery platform technology

Cingulate Overview

Cingulate operates as a holding company. It develops drugs for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety associated disorders through its subsidiary. The company is headquartered in Kansas City, Kansas, the US.
The operating loss of the company was US$17.5 million in FY2022, compared to an operating loss of US$20.7 million in FY2021. The net loss of the company was US$17.7 million in FY2022, compared to a net loss of US$20.7 million in FY2021.

For a complete picture of Dexmethylphenidate Hydrochloride’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.